These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22988250)

  • 21. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.
    Greenall SA; Donoghue JF; Gottardo NG; Johns TG; Adams TE
    Oncogene; 2015 Mar; 34(13):1658-66. PubMed ID: 24747966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.
    Cho J; Chen L; Sangji N; Okabe T; Yonesaka K; Francis JM; Flavin RJ; Johnson W; Kwon J; Yu S; Greulich H; Johnson BE; Eck MJ; Jänne PA; Wong KK; Meyerson M
    Cancer Res; 2013 Nov; 73(22):6770-9. PubMed ID: 24063894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic insights into the activation of oncogenic forms of EGF receptor.
    Wang Z; Longo PA; Tarrant MK; Kim K; Head S; Leahy DJ; Cole PA
    Nat Struct Mol Biol; 2011 Nov; 18(12):1388-93. PubMed ID: 22101934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
    Jain A; Penuel E; Mink S; Schmidt J; Hodge A; Favero K; Tindell C; Agus DB
    Cancer Res; 2010 Mar; 70(5):1989-99. PubMed ID: 20160029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of epidermal growth factor receptor dimerization by BS³ cross-linking.
    Turk HF; Chapkin RS
    Methods Mol Biol; 2015; 1233():25-34. PubMed ID: 25319886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
    Ruan Z; Katiyar S; Kannan N
    Biochemistry; 2017 Jan; 56(1):22-32. PubMed ID: 27936599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain.
    Elleman TC; Domagala T; McKern NM; Nerrie M; Lönnqvist B; Adams TE; Lewis J; Lovrecz GO; Hoyne PA; Richards KM; Howlett GJ; Rothacker J; Jorissen RN; Lou M; Garrett TP; Burgess AW; Nice EC; Ward CW
    Biochemistry; 2001 Jul; 40(30):8930-9. PubMed ID: 11467954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor: association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand.
    Zhu HJ; Iaria J; Orchard S; Walker F; Burgess AW
    Growth Factors; 2003 Mar; 21(1):15-30. PubMed ID: 12795333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-induced dimerization of HARPTPalpha-EGFR chimera suggests a ligand dependent mechanism of regulation for RPTPalpha.
    Blanchetot C; den Hertog J
    FEBS Lett; 2000 Nov; 484(3):235-40. PubMed ID: 11078885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
    Piyush T; Chacko AR; Sindrewicz P; Hilkens J; Rhodes JM; Yu LG
    Cell Death Differ; 2017 Nov; 24(11):1937-1947. PubMed ID: 28731466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors.
    Macdonald-Obermann JL; Pike LJ
    J Biol Chem; 2018 Aug; 293(35):13401-13414. PubMed ID: 29997256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family.
    Arkhipov A; Shan Y; Kim ET; Dror RO; Shaw DE
    Elife; 2013 Jul; 2():e00708. PubMed ID: 23878723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation.
    Zhou M; Felder S; Rubinstein M; Hurwitz DR; Ullrich A; Lax I; Schlessinger J
    Biochemistry; 1993 Aug; 32(32):8193-8. PubMed ID: 8347619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence.
    He L; Hristova K
    Sci Rep; 2012; 2():854. PubMed ID: 23152945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dimerization of internalized epidermal growth factor receptors.
    Sorkin A; Carpenter G
    J Biol Chem; 1991 Dec; 266(34):23453-60. PubMed ID: 1683870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding.
    Adak S; Yang KS; Macdonald-Obermann J; Pike LJ
    J Biol Chem; 2011 Dec; 286(52):45146-55. PubMed ID: 22069315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells.
    Fernandes H; Cohen S; Bishayee S
    J Biol Chem; 2001 Feb; 276(7):5375-83. PubMed ID: 11087732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
    Furuyama K; Harada T; Iwama E; Shiraishi Y; Okamura K; Ijichi K; Fujii A; Ota K; Wang S; Li H; Takayama K; Giaccone G; Nakanishi Y
    Cancer Sci; 2013 May; 104(5):584-9. PubMed ID: 23387505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.